Multiprotein-engineered cells secreting a multispecific antibody
US-2024344030-A1 · Oct 17, 2024 · US
Multipotent adult stem cells and methods for isolation
US10226485B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10226485-B2 |
| Application number | US-8425605-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 21, 2005 |
| Priority date | Aug 5, 1999 |
| Publication date | Mar 12, 2019 |
| Grant date | Mar 12, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells.
First claim
Opening claim text (preview).
What is claimed is: 1. A cell culture comprising isolated expanded human non-embryonic, non-germ cells, the cells having undergone 22 cell doublings in culture, wherein the cells express CD90 and CD49c and one or more of sox-9, sox-11, hox-A5, and MSX-1, wherein the cell population is derived from human bone marrow. 2. The cell population of claim 1 , further expressing telomerase. 3. The cell population of claim 1 , wherein the cell population differentiates into cardiac muscle cells. 4. The cell population of claim 1 , expressing at least one trophic factor selected from the group consisting of IL-6, VEGF, MCP 1 and BDNF. 5. A pharmaceutical composition comprising the cell population of any of claims 1 - 4 .
Assignees
Inventors
Classifications
- A61K35/28Primary
Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title
Genetically modified cells · CPC title
Leukemia inhibitory factor [LIF] · CPC title
RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase · CPC title
Use of cells in diagnostics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10226485B2 cover?
- The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells.
- Who is the assignee on this patent?
- Furcht Leo T, Verfaillie Catherine M, Reyes Morayma, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K35/28. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).